Signifier Medical Technologies
Improving quality of life, sleep and relationships by tackling the root cause of snoring.
Driving Innovation in the Sleep Market
Signifier Medical Technologies (SMT), previously known as Snoozeal® , is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.
Pioneers in challenging the wisdom of conventional snoring and sleep apnoea treatments, we’ve created the first daytime therapy that tackles the root cause of sleep disordered breathing by physiologically retraining the airway against collapse.
We aspire to revolutionise the sleep market with a novel and ground-breaking device that will help solve the conditions of snoring and mild sleep apnoea, making a real impact on the lives of millions of people globally, in an area with significant unmet medical need.
Working in a multidisciplinary sleep team, Snoozeal co-founder Professor Anshul Sama, was deeply empathic with many of his patients who were struggling with conventional treatment options that had failed to change in the last two decades.
Professor Anshul Sama FRCS
BMedSci, BM, BS and FRCS (Gen Surg) and FRCS (OTOL)
Professor Anshul Sama practices in the field of rhinology with a special interest in sleep disordered breathing, frontal sinus surgery and endoscopic skull base surgery.
As a member of the Nottingham Sleep Centre, Professor Sama has established expertise in snoring and sleep disorders, which is recognised at international level.
Over the years Professor Sama came across many devices. All of which had problems:
- They had to be worn during sleep
- Many were invariably uncomfortable
- Only treated the symptom, not the cause
- Only effective when in use
- Further disrupted the already poor sleep quality
- Only temporarily alleviated the problem
- Enslaved users to lifelong use
Wanting to disrupt this dependence on products that had to be worn during sleep, Professor Sama launched the initiative into developing the world’s first, unique daytime treatment for sleep disordered breathing – Snoozeal® .
Three years of devoted effort by many highly skilled professionals from sleep medicine, maxilofacial surgery, product development, medical engineering, software engineers and regulatory experts, has led to a simple, intuitive, non-intrusive and safe product that is clinically proven to treat the root cause of sleep disordered breathing.
Chairman of the Board
Mr Gallahue has over 30 years of strategic, operational and corporate management experience in the healthcare industry, with strong experience in the medical technologies field. Most recently he was Chairman and Chief Executive Officer of CareFusion Corporation, a global health and medical device company. Previously, he was President and Chief Executive Officer of ResMed Inc., a global leader in medical equipment for treating, diagnosing and managing sleep-related respiratory disorders. He has also served on the Board of Directors and Executive Committee of the Advanced Medical Technology Association (AdvaMed) and on the board of directors of Volcano Corporation until its sale to Philips in 2015.
Board Member, CEO & Co-Founder
Mr Kastner has extensive of experience in private debt and equity investing, M&A and corporate finance. He was a Managing Director at Goldman Sachs, where he co-headed the firm’s credit investing business in Europe.
Mr Sullivan is a former CEO, COO and founder of Capital Holdings and current Regional President of Fifth Third Bancorp.
Peter Cistulli holds the ResMed Chair in Sleep Medicine at the University of Sydney, where he leads the Sleep Research Theme within the multidisciplinary Charles Perkins Centre. Prof Cistulli is also a former President of the Australasian Sleep Association and a former board member of the Sleep Health Foundation.
Dr Aditi Desai is the President of the British Society of Dental Sleep Medicine (BSDSM) and an expert dental surgeon with a special interest in sleep medicine. She has served on the Odontological Council and Sleep Medicine Council of the Royal Society of Medicine (RSM) and is on the Board for the Association for Respiratory Technology and Physiology, UK (ARTP).
Dr Richard Schwab is a professor of medicine at the Hospital of the University of Pennsylvania and is affiliated with Hospitals of the University of Pennsylvania-Penn Presbyterian. Dr Schwab’s groundbreaking research has focused on the pathogenesis of obstructive sleep apnoea utilising novel upper airway imaging techniques.
Join our team
At Signifier Medical Technologies we offer a range of exciting career opportunities. We value our employees and strive to create a work environment that is both satisfying and enjoyable.
Signifier® Medical Technologies to host webinar on Precision Medicine and Non-Invasive therapies for Mild Obstructive Sleep Apnea
Signifier® Medical Technologies Hosted a Global Webinar on: “Latest Advances in the Management of Sleep Disordered Breathing”
Signifier® Medical Technologies to host webinar on precision medicine for obstructive sleep apnoea and emerging technologies
- Prospective cohort study of 50 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15) with 46 completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period